natgillin/translations-raw huggingface dataset:
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. antigeenejä (viruksen pinnalla olevia proteiineja).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. greippimehua.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. haittavaikutukset ovat siedettäviä.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. harvemmin potilaille, joilla on munuaisongelmia.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. heikentymiseen ja jopa sokeuteen.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hoidossa Velcadea käytetään yhdessä rituksimabin, syklofosfamidin, doksorubisiinin ja prednisonin kanssa.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hoitamisesta, ja hänen tulee myös valvoa hoitoa.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. hydrokortisonia.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. immuunijärjestelmää hyökkäämään kasvainta vastaan.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. injektoida Coagadexin itse saatuaan siihen asianmukaisen opastuksen.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. jälkeen annos on otettava välittömästi.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kaksi pienempää vahvuutta.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kaksinkertaistaa, kunnes saavutetaan tehokkain annos.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kulunut vähintään 30 minuuttia.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. kutsutaan annoslisäykseksi.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. leikkausta kivun lievittämiseksi.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. luovuttajan T-solut erotetaan muista siirteen soluista.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. lääkkeen itse saatuaan siihen asianmukaisen opastuksen.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. mukaan.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. oleva.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. on annettava ennen RSV-kauden alkua.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. on lopetettava pysyvästi.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. painokiloa kohden.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. puuttui ovulaatio.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. pääasiassa lapsilla, ja se aiheuttaa verisuonten tulehdusta.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. sekä potilaan kliininen tila, ikä ja paino.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. seurataan kerran kuukaudessa erityisesti annoksen muuttamista varten.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. sianrehuun sikojen omistaja yksittäisten sikojen hoitamista varten.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. signaaleja silmästä aivoihin) vaurioitumisen riskiä.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. syöpäsolut kasvavat nopeammin.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. tavanomaiset antibiootit eivät tehoa.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. tenofoviiridisoproksiilia erillisinä valmisteina.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. tiettyjä sivuvaikutuksia.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. triatsolaamiin (muita unilääkkeitä).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. uusiutunut (relapsivaiheen) munasarjasyöpä, joka on herkkä platinaa sisältäville lääkkeille.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vanhemmilta peritty geneettinen poikkeavuus).
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vasta-aineita.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vastaan.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. vuoksi.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. yhdessä metformiinin kanssa.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. yhdistelmätekniikalla.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. ääreisvaltimosairaus (valtimoverenkierron ongelmia).
Reproduction is authorised provided the source is acknowledged.
Tarkempaa tietoa HyQvian käytöstä on pakkausselosteessa.
Reproduction is authorised provided the source is acknowledged.
© European Medicines Agency, 2013.
Reproduction is authorised provided the source is acknowledged. able to produce antibodies more quickly when it is exposed to any of these virus strains.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. advanced hypereosinophilic syndrome (HES) or chronic eosinophilic leukaemia (CEL), diseases in which eosinophils (another type of white blood cell) start growing out of control.
Reproduction is authorised provided the source is acknowledged. edennyt hypereosinofiilinen syndrooma (HES) tai krooninen eosinofiilileukemia.
Reproduction is authorised provided the source is acknowledged. advanced renal cell carcinoma (a type of kidney cancer), when the cancer has worsened despite treatment with a ‘VEGF-targeted’ medicine (a type of medicine that blocks the effects of vascular endothelial growth factor proteins).
Reproduction is authorised provided the source is acknowledged. edennyt munuaissolukarsinooma (erääntyppinen munuaissyöpä), kun syöpä on pahentunut huolimatta hoidosta VEGF:ään kohdistuneella lääkkeellä (eräs lääke, joka estää vaskulaarinen endoteelikasvutekijä -proteiinien toiminnan).
Reproduction is authorised provided the source is acknowledged. after the end of the operation.
Reproduction is authorised provided the source is acknowledged. päättymisestä.
Reproduction is authorised provided the source is acknowledged. after the sodium chloride injection.
Reproduction is authorised provided the source is acknowledged. radionuklidinen myokardiaalinen perfuusiokuvannus, joka alkaa injisoimalla radioaktiivista ainetta 10 - 20 sekuntia natriumkloridi-injektion jälkeen.
Reproduction is authorised provided the source is acknowledged. already taking, together with the lowest dose (5 mg) of empagliflozin.
Jäljentäminen on sallittua, kunhan lähde mainitaan. metformiinia kuin aiemminkin, ja pienimmän annoksen (5 mg) empagliflotsiinia.
Reproduction is authorised provided the source is acknowledged. altogether if side effects are severe.
Reproduction is authorised provided the source is acknowledged. esiintyy, tai lopettaa hoidon kokonaan, jos haittavaikutukset ovat vakavia.
Reproduction is authorised provided the source is acknowledged. always be given to patients in a place where these reactions can be managed immediately if they occur.
Reproduction is authorised provided the source is acknowledged. jälkeen ja Benlysta pitäisi antaa potilaille aina sellaisessa paikassa, missä näitä reaktioita voidaan hoitaa heti niiden ilmetessä.
Reproduction is authorised provided the source is acknowledged. animals are exposed to Erysipelothrix rhusiopathiae bacteria, the immune system will be able to respond more quickly.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. animals are exposed to the same type of bluetongue virus, the immune system will be able to produce antibodies more quickly.
Reproduction is authorised provided the source is acknowledged. myöhemmin altistuvat samantyyppiselle sinikielivirukselle, niiden immuunijärjestelmä kykenee tuottamaan nopeammin vasta-aineita.
Reproduction is authorised provided the source is acknowledged. animals’ immune system recognises the viruses as ‘foreign’ and makes antibodies against them.
Reproduction is authorised provided the source is acknowledged. lampaille ja naudoille, eläimen immuunijärjestelmä tunnistaa viruksen ”vieraaksi” ja muodostaa vasta- aineita sitä vastaan.
Reproduction is authorised provided the source is acknowledged. any other treatments, so the results were judged against historical controls (the results expected in untreated patients, based on past studies).
Reproduction is authorised provided the source is acknowledged. havaintojen perusteella (hoitamattomilla potilailla odotettavissa olevat tulokset, jotka perustuvat aikaisempiin tutkimuksiin).
Reproduction is authorised provided the source is acknowledged. attacking and damaging nerve cells.
Reproduction is authorised provided the source is acknowledged. pääse hyökkäämään hermosoluja vastaan ja vaurioittamaan niitä.
Reproduction is authorised provided the source is acknowledged. be able to respond more quickly.
Reproduction is authorised provided the source is acknowledged. vasta-aineita.
Reproduction is authorised provided the source is acknowledged. be increased in 1.5-mg steps no more frequently than every two weeks, to a regular dose of 3 to 6 mg twice a day.
Reproduction is authorised provided the source is acknowledged. annoksen, annosta voidaan lisätä 1,5 mg kerrallaan, ei kuitenkaan useammin kuin kahden viikon välein, kunnes se on 3–6 mg kahdesti vuorokaudessa.
Reproduction is authorised provided the source is acknowledged. before or after a meal.
Reproduction is authorised provided the source is acknowledged. tunti aterian jälkeen.
Reproduction is authorised provided the source is acknowledged. between two and 18 years, the dose of CellCept is calculated depending on height and weight and should be given by mouth.
Hoidettaessa 2 - 18 -vuotiaita lapsia CellCept-annos lasketaan pituuden ja painon mukaan ja lääke annetaan suun kautta.
Reproduction is authorised provided the source is acknowledged. bisquinolone.
Reproduction is authorised provided the source is acknowledged. malarialääkkeitä, jotka tappavat P. falciparum -loisen.
Reproduction is authorised provided the source is acknowledged. blood glucose levels are usually controlled well on diet, but are experiencing temporary loss of blood glucose control.
Reproduction is authorised provided the source is acknowledged. potilaalle.
Reproduction is authorised provided the source is acknowledged. bodyweight in cats.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. bodyweight, which should last less than a minute; this is followed immediately after by an infusion at a rate of 4 micrograms per kilogram each minute.
Reproduction is authorised provided the source is acknowledged. mikrogrammaa kiloa kohden minuutissa.
Reproduction is authorised provided the source is acknowledged. bone metastases (when cancer has spread to the bone) if they have mild to moderately reduced kidney function.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. botulism, where patients suffer from muscle weakness and paralysis.
Reproduction is authorised provided the source is acknowledged. jossa potilas kärsii lihasheikkoudesta ja paralyysista.
Reproduction is authorised provided the source is acknowledged. bronchial hyperresponsiveness (a state in which the airways of the lungs narrow easily).
Reproduction is authorised provided the source is acknowledged. kasvaville Bronchitol-annoksille aina 400 mg:n kokonaisannokseen asti.
Reproduction is authorised provided the source is acknowledged. carbohydrates.
Reproduction is authorised provided the source is acknowledged kasvuhormoni.
Reproduction is authorised provided the source is acknowledged. catechol-O-methyl transferase (COMT).
Reproduction is authorised provided the source is acknowledged
Reproduction is authorised provided the source is acknowledged. certain ‘antioxidant’ genes involved in protecting cells from damage.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. chicks).
Reproduction is authorised provided the source is acknowledged. kuoriutumaton poikanen).
Reproduction is authorised provided the source is acknowledged. consecutive doses should be 5 micrograms.
Reproduction is authorised provided the source is acknowledged. lopettaa lääkkeen vapauttamisen, kun oikea annos on saatu.
Reproduction is authorised provided the source is acknowledged. continue for several months to prevent the disease coming back, or for longer in patients who have had repeated periods of depression in the past.
Niiden potilaiden hoitoa, joilla Duloxetine Lilly tehoaa, tulee jatkaa useiden kuukausien ajan, jotta ehkäistäisiin sairauden uusiutuminen, tai vielä pitempään niillä potilailla, joilla on ollut toistuvia masennuskausia aiemmin.
Reproduction is authorised provided the source is acknowledged. continuing treatment with Memantine LEK should be reassessed on a regular basis.
Reproduction is authorised provided the source is acknowledged. jälkeen Memantine LEK -hoidon jatkamisen hyötyä on arvioitava säännöllisesti uudelleen.
Reproduction is authorised provided the source is acknowledged. controlling the growth of the lining of the womb.
Reproduction is authorised provided the source is acknowledged. kohdun limakalvon kasvun säätelyyn.
Reproduction is authorised provided the source is acknowledged. cycle, Vargatef is given on days 2 to 21 with docetaxel being given on day 1.
Reproduction is authorised provided the source is acknowledged. päivänä 1.
Reproduction is authorised provided the source is acknowledged. damage.
Reproduction is authorised provided the source is acknowledged. esiintyvän prostaglandiinin keinotekoinen kopio).
Reproduction is authorised provided the source is acknowledged. day is not recommended.
Reproduction is authorised provided the source is acknowledged. vuorokaudessa.
Reproduction is authorised provided the source is acknowledged. day.
Reproduction is authorised provided the source is acknowledged. kaksinkertaistaa, kunnes saavutetaan tehokkain annos.
Reproduction is authorised provided the source is acknowledged. delay the dose in patients who experience severe side effects.
Reproduction is authorised provided the source is acknowledged. lykkäämään sen antamista niille potilaille, joille kehittyy vakavia haittavaikutuksia.
Reproduction is authorised provided the source is acknowledged. diagnosed.
Reproduction is authorised provided the source is acknowledged. sukkulamatotartunta.
Reproduction is authorised provided the source is acknowledged. divided into two or three doses.
Reproduction is authorised provided the source is acknowledged. jaettuna kahteen tai kolmeen antokertaan.
Reproduction is authorised provided the source is acknowledged. dose can be increased to 80 mg, or another medicine for hypertension can be added, such as hydrochlorothiazide.
Reproduction is authorised provided the source is acknowledged. nostaa 80 mg:aan päivässä tai hoitoon voidaan lisätä toinenkin verenpainelääke, kuten hydroklooritiatsidi.
Reproduction is authorised provided the source is acknowledged. dose of 100 mg twice a day.
Reproduction is authorised provided the source is acknowledged. ylläpitoannos kahdesti päivässä.
Reproduction is authorised provided the source is acknowledged. dose of the sulphonylurea or insulin may be considered because of the risk of hypoglycaemia (low blood sugar).
Reproduction is authorised provided the source is acknowledged. insuliinin kanssa, on kuitenkin harkittava sulfonyyliurea- tai insuliiniannoksen pienentämistä hypoglykemian (matalan verensokerin) riskin vuoksi.
Reproduction is authorised provided the source is acknowledged. dose should be assessed within 3 months after starting treatment, and from then on the benefits of continuing treatment with Memantine Mylan should be reassessed on a regular basis.
Reproduction is authorised provided the source is acknowledged. kuukauden kuluttua hoidon aloittamisesta, minkä jälkeen Memantine Mylan -hoidon jatkamisen hyötyjä on arvioitava säännöllisesti uudelleen.
Reproduction is authorised provided the source is acknowledged. drainage of the watery fluid (aqueous humour) out of the eyeball.
Reproduction is authorised provided the source is acknowledged. virtausta pois silmämunasta.
Reproduction is authorised provided the source is acknowledged. due to side effects, especially during the first eight weeks of therapy.
Reproduction is authorised provided the source is acknowledged. etenkin kahdeksan ensimmäisen hoitoviikon aikana.
Reproduction is authorised provided the source is acknowledged. dummy treatment).
Reproduction is authorised provided the source is acknowledged. annoksena kahdesti vuorokaudessa) verrattiin lumelääkkeeseen.
Reproduction is authorised provided the source is acknowledged. each other.
Reproduction is authorised provided the source is acknowledged. keskenään.
Reproduction is authorised provided the source is acknowledged. edoxaban from the body.
Reproduction is authorised provided the source is acknowledged. estäjiksi), sillä ne voivat häiritä edoksabaanin poistumista elimistöstä.
Reproduction is authorised provided the source is acknowledged. effect on calcium channels.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. effectiveness of the medicine in improving lameness, pain on manipulation/palpation, joint swelling and ability to move.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. ensure that they are above set minimum levels.
Reproduction is authorised provided the source is acknowledged. suuremmat.
Reproduction is authorised provided the source is acknowledged. epithelial cancer of the ovary, cancer of the fallopian tube (that connect the ovaries to the uterus) or the peritoneum (the membrane lining the abdomen).
Reproduction is authorised provided the source is acknowledged. kohdunkaulansyöpä, joka on hoitoon vastaamaton, uusiutunut tai metastoitunut.
Reproduction is authorised provided the source is acknowledged. events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.
Reproduction is authorised provided the source is acknowledged. sydänkohtaukseen tai halvaukseen liittyvä riskitekijä, mutta jotka eivät voi ottaa K- vitamiiniantagonisteja (muita veritukoksia ehkäiseviä lääkkeitä) ja joilla on vähäinen verenvuodon riski.
Reproduction is authorised provided the source is acknowledged. events such as a heart attack or stroke, cannot take vitamin K antagonists (other medicines that prevent blood clots) and are at low risk of bleeding.
Reproduction is authorised provided the source is acknowledged. vitamiiniantagonisteja (muita veritukoksia ehkäiseviä lääkkeitä) ja joilla on vähäinen verenvuodon riski.
Reproduction is authorised provided the source is acknowledged. expanded in the laboratory to provide enough cells to make up a suspension of cells that can be used to treat the cartilage defect.
Reproduction is authorised provided the source is acknowledged. potilaan rustovauriokohtaan polvileikkauksessa.
Reproduction is authorised provided the source is acknowledged. exposed to the bluetongue virus, the immune system will be able to produce antibodies more quickly.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. first food or drink of the day.
Reproduction is authorised provided the source is acknowledged. vähintään 30 minuuttia ennen päivän ensimmäistä ruoka- tai juoma-annosta.
Reproduction is authorised provided the source is acknowledged. five minutes on days 1 and 8 of each cycle.
Reproduction is authorised provided the source is acknowledged.
Reproduction is authorised provided the source is acknowledged. fluids and so reducing diarrhoea.
Reproduction is authorised provided the source is acknowledged. vähenee.
Reproduction is authorised provided the source is acknowledged. for a further four doses.
Reproduction is authorised provided the source is acknowledged. ylläpitoannosta neljän viikon välein.
Reproduction is authorised provided the source is acknowledged. for Qutenza to have an effect.
Reproduction is authorised provided the source is acknowledged. puhdistusgeeliä.
Reproduction is authorised provided the source is acknowledged. for which standard antibiotics do not work.
Reproduction is authorised provided the source is acknowledged. on osoitettu tehoavan bakteereihin, joihin tavanomaiset antibiootit eivät tehoa (kuten metisilliiniresistenttiin Staphylococcus aureukseen (MRSA)).
Reproduction is authorised provided the source is acknowledged. from a different class of medicines used in pre-term labour called beta-agonists).
Reproduction is authorised provided the source is acknowledged. joka on toinen ennenaikaisissa synnytyksissä käytettävä lääkeryhmä).
Reproduction is authorised provided the source is acknowledged. from then on the benefits of continuing treatment with Memantine ratiopharm should be re-assessed on a regular basis.
Reproduction is authorised provided the source is acknowledged. aikana 15 mg.
Reproduction is authorised provided the source is acknowledged. gastric adenocarcinoma (a type of stomach cancer) in patients who have not yet received any treatment for their cancer.
Reproduction is authorised provided the source is acknowledged. eturauhassyöpä, kun syöpä ei vastaa hormonihoitoon.